Nowon 365mc Hospital’s Medical Director, Dr. Chae Kyu-hee, Presents at the 2025 365mc International Liposuction & LAMS Conference
Dr. Chae Kyu-hee, Medical Director of Nowon 365mc Hospital, presented “Wegovy vs. Mounjaro: Differentiated Prescription Strategies” at the 2025 365mc International Liposuction & LAMS Conference in Seoul. As session chair for the “Innovations in LAMS” segment, Dr. Chae highlighted his extensive experience in obesity pharmacology and the future of medical weight-loss therapy.
Hello, this is Lipomaniac 365mc.
On Sunday, November 2, Dr. Chae Kyu-hee, Medical Director of Nowon 365mc Hospital, delivered a lecture at the 2025 365mc International Liposuction & LAMS Conference, held at the Grand Mercure Ambassador Hotel.
■ Date: November 2, 2025 (Sun)
■ Venue: Grand Mercure Ambassador Hotel
■ Topic: Wegovy vs. Mounjaro: Differentiated Prescription Strategies
The 365mc International Liposuction & LAMS Conference is an annual academic meeting attended by 365mc medical directors from Korea and abroad. Its purpose is to advance surgical expertise across all branches, standardize medical skills, and facilitate high-level technique sharing.
At this year’s highly successful conference, Dr. Chae served as the session chair for the “Innovations in LAMS” segment and also delivered a lecture on prescription strategies for the globally recognized anti-obesity medications Wegovy and Mounjaro, drawing strong interest from attending physicians.
For more than 20 years, Dr. Chae has dedicated his career exclusively to fat-focused treatment alongside 365mc—conducting clinical research, delivering lectures on obesity prescription strategies, and publishing the comprehensive textbook Clinical Obesity Pharmacology, which reflects his accumulated expertise. His presentation at the conference was praised as being fully worthy of his reputation.
Moving forward, 365mc will continue collaborating with Dr. Chae to share clinical experience, obesity pharmacotherapy knowledge, and LAMS innovations with leading experts worldwide—while striving to advance global obesity treatment standards.
Thank you.
